Bang Holding Corp. (OTC: BXNG), Cara Therapeutics Inc. (NASDAQ: CARA), Zynerba Pharmaceuticals Inc. (NASDAQ: ZYNE), Terra Tech Corp. (OTC: TRTC), General Cannabis Corp. (OTC: CANN).
Individual voters will be analyzing such things as tax revenue implications, the general shift or perception of cannabis and how the industry will have an effect on the general safety. With this in mind, the cannabis industry will experience a histrionic change if even a few states permit legislation correlated to cannabis regulatory restructuring next month.
Bang Holdings Corporation (OTCQB: BXNG), through its subsidiary "Bang Digital Media", provides digital content and inclusive marketing to the cannabis industry. Bang Digital Media promotes cannabis-related businesses to over a million supporters by using its expanded network of cannabis-friendly social media influencers. Eventually, Bang Digital Media links cannabis-friendly establishments to cannabis fanatics.
In mid-August, the company has reached a milestone of a million subscribers across its social networks and currently has over 1.25 million subscribers with its content being actively viewed more than 72.5 million times and significantly growing the importance of its marketing network on a daily basis. The constant increase in the number of subscribers and its engagement, to the Company's active community, new influencers it continues to sign, together with rapidly rising curiosity in cannabis nationwide as several forms of its legalization are progressively escalating all across the states, including the District of Columbia.
"This is an incredibly exciting time for Bang," Steve Berke, CEO of Bang Holdings said. "Our online content is attracting new users every day and surpassing one million subscribers proves we are significantly expanding the reach, along with the advertising value, of our network. We are now settled in and are operating out of our regional production office in Denver, the Epicenter of Ganjapreneurialism and home to so many innovators and entrepreneurs in the cannabis industry, Berke added. "It enables us to better serve our industry customers locally, and to keep a finger on the pulse of the newest market innovations and hottest trends."
Cannabis-focused agriculture company, Terra Tech Corp. (OTCQX: TRTC) announced that Blüm has opened a new retail facility in the City of San Leandro, California. Blüm is a retail medical cannabis facility concentrated on providing medical cannabis to patients who seek for alternative treatments for their chronic medical conditions. Terra Tech expects to start construction of the new facility in January 2017. The new Blüm location in San Leandro will considerably increase the accessibility of the Company's proprietary IVXX™ brand of premium medical cannabis, flowers, shatter, wax and oil, in addition to other superior grade medical cannabis products from a range of trustworthy suppliers.
Clinical-stage biopharmaceutical company, Cara Therapeutics Inc. (NASDAQ: CARA), has reported that the effects of cannabis has led to an endogenous system of ligands in individuals associated in a number of physiological processes that include pain and inflammation. Cara owns CR701, a subsidiary performing cannabinoid receptor pain drug and CR845, Cara's top pain treatment. Cara's Chief Medical Officer, Dr. Joseph Stauffer will also be participating at the 10th Annual Pain & Migraine Therapeutics Summit as well as at the ANESTHESIOLOGY® 2016 conference.
Clinical-stage pharmaceutical company devoted to the development of advanced transdermal synthetic cannabinoid treatments, Zynerba Pharmaceuticals Inc. (NASDAQ: ZYNE) provided an update for its drug-adhesive matrix transdermal patch, ZYN001 and synthetic CBD that is a patent-protected permeation-enhanced gel, the ZYN002. Zynerba will start Phase 1 clinical trials for ZYN001 during the first half of 2017 and Phase 2 clinical trials will begin during the second half. As for ZYN002, three Phase 2 clinical trials will remain on schedule to report results during the first half of 2017. Two Phase 2 clinical trials are currently ongoing for ZYN002, in adults with refractory epilepsy and in knee pain related with osteoarthritis. Phase 2 clinical trials in patients with Fragile X Syndrome will start before the end of this year.
General Cannabis Corp. (OTCQB: CANN) is the all-in-one resource for top quality service providers available to the regulated Cannabis Industry. CANN is a partner to the cultivation, production and retail side of the cannabis business. The company does this through a combination of operating divisions such as real estate, consulting, security, financing and the distribution of vital infrastructure products to cultivate facilities and dispensaries. As a holding company, its subsidiaries are able to leverage the strengths of each other to succeed.
Subscribe Now! Watch us report from NYSE https://www.youtube.com/FinancialBuzzMedia
For "The Latest Buzz in Financial News", SIGN UP & Visit: http://www.FinancialBuzz.com
Follow us on Twitter for real time Financial News Updates: https://twitter.com/financialbuzz
Follow and talk to us on Instagram: https://www.instagram.com/financialbuzz
Facebook Like Us to receive live feeds: https://www.facebook.com/Financialbuzz/
FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR branding, marketing and advertising for third parties for disseminating news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.
For further information:
Media Contact: firstname.lastname@example.org , +1-877-601-1879